Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Tuning In To Your Cat
Anyone who has ever had cats knows how difficult it can be to get them to do anything they don"t already want to do. But it seems that the house cats themselves have had distinctly less trouble getting humans to do their bidding, according to a report published in the July 14th issue of Current Biology, a Cell Press publication.
generic viagra online
Identifying Genetic Markers Related To Drug Induced Liver Injury
The International Serious Adverse Events Consortium (SAEC) has announced initial results from its research designed to discover genetic markers that may predict individuals at risk for serious drug induced liver injury (DILI). The SAEC is a nonprofit research corporation, launched in the fall of 2007, comprised of and funded by 10 leading pharmaceutical companies and the Wellcome Trust. The U.S. Food and Drug Administration (FDA) also contributes to the scientific and strategic direction of this novel research effort. The collection and initial characterization of the DILI cases supporting these results was performed by the UK-based DILIGEN network, led by Professor Ann Daly and colleagues at Newcastle University, but also involving researchers at the University of Liverpool and at Queen"s Medical Centre, Nottingham.
News of the day
Helping Older Adults Transition From Hospital To Home
Program is top priority under new health care imperatives to reduce the rate of 30-day readmissions
Endocrinology

Bovie Medical Corporation Announces 510K Submission To The FDA For Its BOSS Soft Tissue Coagulation Device

Bovie Medical Corporation (the "Company") (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, announced a 510K submission to the FDA seeking pre-market clearance for Bovie"s BOSS for surgical applications where soft tissue bipolar coagulation is desired. The BOSS is the latest generation device based on Bovie"s saline enhanced sintered steel technology. The BOSS delivers RF energy simultaneously with saline to perform coagulation of soft tissue and bone, with minimal smoke, charring and sticking of tissue as well as reduced blood loss. Saline enhanced surgeries reduce operating time while improving post-operative outcomes and shortens recovery time. The BOSS will primarily be targeted towards orthopedic hip and knee reconstruction surgeries, which are significant markets, with over 1.3 million procedures performed in the United States annually. These procedures represent large and growing markets due to a more active and aging population. The worldwide market is expected to exceed $500 million in 2009. Andrew Makrides, president of Bovie, stated, "In today"s economic environment, where controlling medical costs is important, the BOSS technology meets the needs of patients, surgeons and hospitals. Reduced blood loss, shortened operating and recovery time makes the BOSS a technology product that targets a large and growing market." For further information about the Company"s current and new products, please refer to the Investor Relations section of Bovie"s website http://www.boviemedical.com. Bovie Medical Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009